WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS

WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS

Saved in:

Bibliographic Details
Main Authors:	Dmitrij Kollins, Olympia Papachristofi, Thomas Hach, Severina Jacinto-Sanders, Tobias Merkel, Robert Schmouder, Kenneth Kulmatycki, Ronny Renfurm, Vlado Perkovic
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924023842
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN25-1585 A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-1084 INTERNATIONAL RISK-PREDICTION TOOL IN IgAN AND THE PROGNOSTIC IMPLICATIONS OF CRESCENTS
by: Beatriz Mendes, et al.
Published: (2025-02-01)

WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL
by: Richard Lafayette, et al.
Published: (2024-04-01)

Burden of corticosteroid therapy in patients with immunoglobulin A nephropathy (IgAN): a systematic literature review
by: Sarah N. Ali, et al.
Published: (2025-05-01)

WCN25-4528 POST TRANSPLANT CRESCENTIC IgAN- FIRST CASE SERIES FROM INDIA
by: NITISH THAKUR, et al.
Published: (2025-02-01)

2bRAD-M reveals circulating microbiome in chronic antibody-mediated rejection (CAMR) and IgA nephropathy (IgAN) after kidney transplantation
by: Yan-Xin Tao, et al.
Published: (2025-07-01)

WCN25-52 EPIDEMIOLOGY OF IMMUNOGLOBULIN A NEPHROPATHY (IgAN) AND OCCURRENCE OF PROTEINURIA IN CHINA: EVIDENCE FROM SYSTEMATIC REVIEW AND META-ANALYSIS
by: Zhaoxin Chen, et al.
Published: (2025-02-01)

Evaluation the Efficacy of ELISA IgG, IgM and IgA Tests for Diagnosis of Helicobacter pylori
by: Hogir Mohammed Shukri Saadi, et al.
Published: (2018-09-01)

WCN24-750 ASSESSMENT OF DRUG INTERACTIONS WITH IPTACOPAN
by: Robert Schmouder, et al.
Published: (2024-04-01)

Clinical characteristics of patients with GFAP-IgG coexisting with AQP4-IgG or MOG-IgG
by: Qingchen Li, et al.
Published: (2025-07-01)

Relationship between renal deposition of complement C3， IgG， IgM and pathology in IgA nephropathy
by: Fang-cao Lu, et al.
Published: (2022-08-01)

Detection of IgM, IgG and IgA against pertussis in pregnant women in I - II - III trimesters
by: T. A. Skirda, et al.
Published: (2021-10-01)

Estimation of Ig/M & IgG values in the serum atfer intravenois
by: Baghdad Science Journal
Published: (2005-06-01)

WCN24-748 ASSESSMENT OF THE EFFECT OF HEPATIC IMPAIRMENT ON IPTACOPAN PHARMACOKINETICS
by: Robert Schmouder, et al.
Published: (2024-04-01)

IgM+IgD− B cells in human gut-associated lymphoid tissue have memory features and give rise to IgM+ and IgA+ antibody-secreting cells
by: Ameera M. Bukhari, et al.
Published: (2025-07-01)

Aberrantly Glycosylated IgA1 as a Factor in the Pathogenesis of IgA Nephropathy
by: Mototsugu Tanaka, et al.
Published: (2011-01-01)

Autoantibody profiles in Alzheimer´s, Parkinson´s, and dementia with Lewy bodies: altered IgG affinity and IgG/IgM/IgA responses to alpha-synuclein, amyloid-beta, and tau in disease-specific pathological patterns
by: Luisa Knecht, et al.
Published: (2024-12-01)

IgA Nephropathy in the Elderly
by: Dana V. Rizk, et al.
Published: (2025-08-01)

Serum IgA/C3 ratio as a diagnostic and prognostic biomarker for IgA nephropathy
by: Anitha Swamy, et al.
Published: (2025-08-01)

The diagnostic value of serum IgG4 for the diagnosis of IgG4-related disease: and is that so great?
by: E. V. Sokol, et al.
Published: (2019-03-01)

Corrigendum to “Is childhood IgA nephropathy different from adult IgA nephropathy? A narrative review”
Published: (2025-07-01)

IgM has a better relative distribution in inflammation sites and tumor tissues than IgG
by: Abdulaziz M. Aldayel, et al.
Published: (2025-03-01)

Clinical and diagnostic significance of isolated detection of IgA antibodies to deamidated gliadin peptides in IgA nephropathy patients
by: M. E. Mantsaeva, et al.
Published: (2025-05-01)

Dynamics of chromatin accessibility governing Gd-IgA1 synthesis in B cells associated with IgA nephropathy
by: Yangang Gan, et al.
Published: (2025-07-01)

Persistence of IgE-associated allergy and allergen-specific IgE despite CD4+ T cell loss in AIDS.
by: Katharina Marth, et al.
Published: (2014-01-01)

IgA肾病的治疗进展
by: 刘双信, et al.
Published: (2015-01-01)

Cholangiocarcinoma with respect to IgG4 Reaction
by: Kenichi Harada, et al.
Published: (2014-01-01)

IgM- and IgA-response of peritoneal B-1 cells to the TI-2 antigen with the presence of γδT cells in vitro
by: N. A. Snegireva, et al.
Published: (2021-05-01)

Prevalence of SARS -CoV-2 IgG/IgM antibodies among patients in Zakho City, Kurdistan, Iraq
by: Ali Yahya Saeed, et al.
Published: (2022-07-01)

The Role of Moringa oleifera- Ifalmin® Formulation in Regulation of B220+IgM+ and B220+IgG+ in Diabetic Mice
by: Wahyu Isnia Adharini, et al.
Published: (2020-02-01)

Does the Maternal Serum IgG Level during Pregnancy in Primary Antibody Deficiency Influence the IgG Level in the Newborn?
by: Vasantha Nagendran, et al.
Published: (2015-01-01)

Identification of novel human IgE-binding peptides from a phage display library for total IgE detection
by: Sudtida Kaew-amdee, et al.
Published: (2025-07-01)

LIF/JAK2/STAT1 Signaling Enhances Production of Galactose-Deficient IgA1 by IgA1-Producing Cell Lines Derived From Tonsils of Patients With IgA Nephropathy
by: Koshi Yamada, et al.
Published: (2024-02-01)

What is the role of rapid diagnostic tests for COVID-19 IgM/IgG in the pre-operative period of cosmetic plastic surgery?
by: Rafaela Koehler Zanella, et al.
Published: (2021-03-01)

Adjunctive IgM-enriched immunoglobulin therapy with a personalised dose based on serum IgM-titres versus standard dose in the treatment of septic shock: a randomised controlled trial (IgM-fat trial)
by: Giacomo Grasselli, et al.
Published: (2021-02-01)

Effect and Safety of Finerenone in Patients with IgA Nephropathy
by: Guo Y, et al.
Published: (2025-07-01)

Impact of IgG subclass on monoclonal antibody developability
by: Paul Cain, et al.
Published: (2023-12-01)

Understanding the natural history of selective IgA deficiency
by: Nayara Maria Furquim Nasser, et al.
Published: (2025-07-01)

Specific IgA antibodies in the diagnosis of acute brucellosis
by: Hanan El-Mohammady, et al.
Published: (2011-09-01)

To the 70th anniversary of Prof. I.G. Frolova
by: article Editorial
Published: (2024-11-01)